同时值得关注的是，医渡科技在国际多边合作舞台实现重要突破：上海合作组织国家多功能经贸平台 (上合家园)卫生可持续发展工作委员会近期正式成立，医渡科技成功入选组织成员单位;公司联合创始 人、CEO 徐济铭当选委员会第一届理事，双重认可标志着公司在国际数字健康合作领域的专业能力与 行业地位获得权威背书。 近年来，医渡科技的国际化战略布局稳步推进，业务和客户网络已拓展至全球六个地区。通过与当地政 府部门、医疗机构及科研院所深度协同，构建起了成熟的本土化合作生态，研发的智能化解决方案已广 泛落地于传染病监测预警、全民人口健康管理、AI 辅助诊疗、个性化健康管理等关键领域，持续以科 技力量赋能全球健康事业发展。 智通财经APP获悉，12月19日，医渡科技(02158)公告显示，当日以每股5.23港元的价格回购9.35万股， 回购金额约49万港元。12月以来，公司已回购11次，累计回购约344万股，总金额超1740万港元。以真 金白银持续夯实市场信心，彰显医渡科技对自身发展前景的坚定看好。 消息面上，医渡科技近期在行业认可与国际合作领域捷报频传。在香港城市大学数码医学研究院周年大 会上，公司创始人、董事长宫如璟女士获聘为 ...

来源：喜娜AI 金融市场犹如变幻莫测的海洋，时刻涌动着投资与经济政策的波澜，深刻影响着全球经济的走向。在 此，喜娜AI为您呈上今日财经热点新闻，全方位覆盖股市动态、经济数据、企业财务状况以及政策更 新等关键领域，助您精准洞察金融世界的风云变幻，把握市场脉搏。 12月18日晚间，美光科技盘前大涨约10%，其给出的营收预测高于市场预期，这一消息带动美股三大指 数集体高开。美光科技称人工智能存储需求飙升，产品全面售罄。此外，美国11月CPI同比上涨2.7%低 于预期，进一步提振市场信心，主要股指连续下跌后反弹。投资者关注该数据对美联储货币政策的影 响。详情>> 阿里一周减持三家上市公司，投资布局向AI领域集中 12月12 - 17日，阿里系资本减持华谊兄弟、翱捷科技、红星美凯龙三家上市公司股份。早前美年健康也 公告，阿里旗下公司计划减持。过去两年阿里已减持多家企业，如今似乎加快外部资产减持。同时，其 外部投资正聚焦AI领域，2023年后人工智能领域投资金额占比跃升至50%，今年还新增多笔具身智能领 域投资。此外，阿里也在加大对电商及阿里云业务的投入。详情>> 海南自贸港正式封关，多项政策利好释放 自2025年12月 ...

Core Viewpoint - The article provides an overview of the trading activities in the Shanghai and Shenzhen stock markets, highlighting significant stock transactions, sector performances, and ETF trading volumes. Trading Summary - The total trading volume for the Shanghai and Shenzhen Stock Connect today reached 198.94 billion yuan, with Zhaoyi Innovation and Zhongji Xuchuang leading in individual stock trading volumes [1][2]. - The Shanghai Stock Connect recorded a total trading amount of 94.04 billion yuan, while the Shenzhen Stock Connect reached 104.89 billion yuan [2]. Top Trading Stocks - In the Shanghai Stock Connect, the top traded stocks included: - Zhaoyi Innovation (23.86 billion yuan) - Zijin Mining (16.87 billion yuan) - Luoyang Molybdenum (15.55 billion yuan) [3]. - In the Shenzhen Stock Connect, the leading stocks were: - Zhongji Xuchuang (26.44 billion yuan) - Sunshine Power (26.09 billion yuan) - Xinyi Technology (25.89 billion yuan) [4]. Sector Performance - The mechanical equipment sector saw the highest net inflow of funds, totaling 38.67 billion yuan, with a net inflow rate of 2.91% [6]. - Other sectors with significant net inflows included non-ferrous metals (35.32 billion yuan) and transportation equipment (31.28 billion yuan) [6]. - Conversely, the electronics sector experienced the largest net outflow, amounting to -57.70 billion yuan, with a net outflow rate of -2.26% [7]. ETF Trading Activity - The top ten ETFs by trading volume included: - A500 ETF Huatai Baichuan (13.37 billion yuan) - Hong Kong Securities ETF (10.43 billion yuan) [13]. - The A500 ETF Huatai Baichuan also saw a trading volume increase of 7.50% compared to the previous trading day [13]. - The ETF with the highest growth in trading volume was the Hang Seng Dividend Low Volatility ETF, which surged by 183% [14]. Market Dynamics - The article notes that AI healthcare stock Huaren Health experienced a pullback after a rise, with significant sell-offs from major trading desks [1][19]. - The stock Pingtan Development saw a dramatic drop from a nearly 5% increase to over a 7% decline, despite some buying activity from institutional investors [1][19].

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/12/5-2025/12/18） 29 省耗材联盟集采启动 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 相关报告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 12 月 19 日 分析师：谢雄雄 SAC 执业证书编号： S0 ...

今日市场全线反弹，沪指录得3连阳。盘面上，题材继续轮动，大消费方向持续走强，海南自贸区、可 控核聚变、地产等板块涨幅居前。市场全天成交约1.7万亿，较上个交易日小幅放量，两市上涨个股超 4400只。 对于今日指数全线上涨的原因，分析人士表示，美国11月非农部门就业人数、美国11月消费者价格指数 (CPI)等数据相继公布，日本央行今天上午宣布将目标利率提高25个基点至0.75%，符合市场预期。随着 一系列"靴子"落地，A股短期面临的外部不确定性消散，市场关注点开始转向A股自身内部。 盘面上看，大消费方向再度拉升，零售、乳业、犒赏经济等细分概念领涨，免税概念龙头股中国中免盘 中一度触及涨停，收盘暴涨超8%；海南板块午后涨幅扩大，海汽集团、海南发展、海南海药等多股涨 停；房地产板块震荡反弹，中天服务3连板，三湘印象、华联控股等领涨；核聚变概念大涨，王子新 材、四创电子等多股涨停；AI医疗概念活跃，维康药业、新诺威领涨；汽车产业链震荡上行，浙江世 宝4连板、路畅科技涨停；下跌方面，半导体、贵金属、银行等板块领跌。 展望后市，兴业证券认为，近期重磅会议奠定的国内外积极的政策组合，创造了有利于风险资产演绎的 良好环境，跨 ...

2025 年 12 月 19 日 行业研究 从"低频咨询"到"高频陪伴"，AI 医疗激活"医药险"全链路闭环 ——蚂蚁集团旗下 AI 健康助手"蚂蚁阿福"上线点评 要点 事件： 12 月 15 日，蚂蚁集团将原 AI 健康应用"AQ"正式更名为"蚂蚁阿福"。该产 品在发布后数日内下载量激增，12 月 16 日跃升至苹果应用商店总榜 Top 3， MAU（月活用户）突破 1500 万，位居国内 AI 健康管理类 APP 首位。蚂蚁阿福 接入了 500 多位国家级院士及名医的"AI 分身"，将原本稀缺的顶级专家资源 通过大模型转化为 24 小时在线的"平民化服务"。 点评： 流量入口的重定向，推动高频医疗健康交互。"阿福"通过 AI 降低了健康咨询 门槛，过去互联网医疗的痛点是"低频"，而"AI 陪伴"将医疗拉向了高频健 康管理，成为链接患者与药品、服务的入口。我们认为阿福 AI 陪伴模式有望显 著提升用户活跃度（DAU）与留存率。AI 能够在用户需求产生的早期阶段完成 精准识别与分流，为后端的高毛利药品销售及专业医疗服务实现高效导流。 赋能"医+药+险"全链路闭环。蚂蚁依托支付生态（医保电子凭证）、保险（好 医 ...

Core Insights - The National High-Performance Medical Device Innovation Center released the "2025 Medical Device Industry Innovation Ecosystem Insights" list, highlighting emerging companies, institutions, individuals, and products in China's medical device industry [1] - The assessment covers the entire chain from technology research and development to market application, showcasing the innovative ecosystem of China's medical device industry for 2025 [1] Group 1: Assessment Framework - The evaluation system has evolved from a dual dimension of "companies + individuals" to a comprehensive framework covering seven dimensions, including companies, individuals, products, universities, hospitals, investment institutions, and industrial parks [2] - This comprehensive assessment network achieves full coverage of the innovation chain, industrial chain, and capital chain [2] Group 2: Achievements and Innovations - Over the past five years, the center has made significant breakthroughs in key technologies, including the world's first 5.0T whole-body MRI and the first domestic ECMO, positioning these innovations among the international top tier [2] - The center has completed the domestic manufacturing of ECMO within three years, achieving performance metrics on par with international counterparts, marking a significant milestone in the development of high-end medical equipment in China [2] Group 3: Technological Advancements - The center is focused on strengthening core components and key raw materials, achieving full-chain domestic production for high-performance AFE chips and high-precision medical nickel-titanium materials [3] - In the past five years, the center has undertaken over 120 national and local research tasks, filed 296 patents (with two-thirds being invention patents), and participated in the revision of 11 industry standards [3] Group 4: Strategic Contributions - The center has played a pivotal role in strategic research and planning, contributing to over 30 strategic studies and deeply engaging in the national high-end medical equipment "14th Five-Year" top-level strategic planning [3] - It provides substantial intellectual support for national strategies, government decision-making, industrial resource collaboration, and corporate strategic layout [3]

（原标题：AI医疗热度上升，港股通医疗ETF、恒生医疗ETF涨超2%） 港股通医疗ETF跟踪港股通医疗主题指数，覆盖医疗板块三大细分领域，持仓CXO权重超30%，AI医疗 权重超20%，为市场投资CXO及AI医疗概念提供了便捷工具。 fund 恒生医药ETF聚焦创新药研发、生物科技，持仓阿里健康、微创机器人、荣昌生物、翰森制药、乐普生 物等公司。 对于医疗板块，招商证券指出，回顾二级市场，2025年真正走出持续行情的Healthtech标的仍然有限， 整体表现阶段性滞后于一级市场的高景气度。这种分化并非异常，而是新一轮技术范式演进中的典型特 征：GenAI正沿着以往科技浪潮的路径推进——由底层算力与模型等基础设施起步，逐步向平台层与垂 直应用层扩展。在这一阶段，AI在医疗行业中的渗透与效率释放仍处于价值创造的形成期，技术成熟 度、商业模式可复制性以及医疗体系内部的组织适配，均需要时间逐步兑现。因此，AI对医疗行业的 重塑将是渐进而长期的过程，当前阶段更应把握结构性机会，而非单一主题驱动的交易机会。我们认 为，具备稳定业绩基础、深度嵌入行业核心工作流、同时拥有AI长期可选性的公司，更有望率先实现 价值重估。以V ...

科创创新药ETF国泰（589720）跟踪的是科创新药指数（950161），单日涨跌幅达20%，该指数从科创 板市场中选取涉及生物制药、化学制药等领域的创新药物研发企业作为指数样本，重点关注具有较高研 发投入和创新能力的企业，以反映中国创新药行业上市公司证券的整体表现和发展趋势。 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供参 考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构成 投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产品 要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 12月19日早盘，科创创新药ETF国泰（589720）涨超2.1%。 东方财富证券指出，2025年医药生物行业呈现多重积极趋势。医疗器械招采端持续复苏，设备更新政策 与资金落地驱动需求释放，2025Q3招投标市场规模同比增长29.8%，医疗设备公司收入端拐点显现。国 内集采与医疗反腐常态化背景下，企业加速出海寻求高毛利市场。创新药领域经历十年沉淀进入管线密 集收获期，2024年市场规模突破4 ...

Group 1 - The core viewpoint of the article highlights a rebound in two major sectors of Hong Kong stocks: internet and innovative pharmaceuticals, with the Hong Kong Stock Connect Technology ETF (159101.SZ) rising by 1.5% [1] - Key stocks such as WuXi Biologics increased by over 6%, and WuXi AppTec rose by over 4%, while Tencent, Meituan, and Alibaba experienced slight increases [1] - After three months of adjustment, the crowdedness in these two core sectors has returned to low levels, with recent catalysts for growth including Tencent's release of the mixed reality model and Baidu's Kunlun chip accelerating towards an IPO, projected to exceed 2 billion yuan in revenue by 2025 [1] Group 2 - The passing of the U.S. National Defense Authorization Act for fiscal year 2026 on December 18 is seen as beneficial for CXO companies like WuXi Biologics and WuXi AppTec, as the new version of the biosafety law does not specifically name any companies [1] - Improved relations between the two countries have also boosted market risk appetite [1] - The Hong Kong Stock Connect Technology ETF (159101.SZ) tracks the National Index for Hong Kong Stock Connect Technology, which has reduced exposure to consumer retail while increasing allocation to biopharmaceuticals and hardware equipment, allowing for greater index elasticity [1]